The recently developed therapy, treatment with Spinraza/Nusinersen (Biogen), has been shown to increase the level of SMN and improve the symptoms of SMA patients (Corey, 2017; Finkel et al., 2016; Passini et al., 2011). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.